There are several surgical approaches for uterine fibroids treatment for women with symptomatic fibroids to choose from and overcome symptoms such as heavy menstrual bleeding, pelvic pressure, and frequent urination. These procedures include, endometrial ablation, MRI guided procedures, hysterectomy, myomectomy, uterine artery embolization, and radiofrequency ablation, among others. These procedures have various applications. Hysterectomy is for women who have lost their fertility. Different types of devices used for the treatment of uterine fibroids include, power morcellators, hysteroscope, intra uterine devices, catheters, endometrial ablation devices, radiofrequency ablation devices, and other devices.
U.S. uterine fibroids treatment market is estimated to account for US$ 243.5 Mn in terms of value in 2020 and is expected to reach US$ 298.5 Mn by the end of 2027.
U.S. Uterine Fibroids Treatment Market: Drivers
Widespread availability of diagnostic tests is expected to propel growth of the U.S. uterine fibroids treatment market over the forecast period. For instance, pelvic examination and vaginal ultrasound are widely available and inexpensive diagnostic tests. Vaginal ultrasound is considered gold standard evaluation tool for uterine fibroids, owing to its ability to reconstruct the coronal plane of the uterus by three‐dimensional imaging technology.
U.S. Uterine Fibroids Treatment Market: Opportunities
Development of alternatives to current surgical and expensive approaches is expected to offer lucrative growth opportunities for players in the market. Selective progesterone receptor modulators (SPRMs) can be considered an alternative to surgical therapy.
U.S. Uterine Fibroids Treatment Market: Restraints
Stringent regulations and urinary tract injuries are expected to hinder growth of the U.S. uterine fibroids treatment market. Companies that develop, manufacture, and sell medical devices are subject to certain governmental regulations laid down by the U.S. FDA. To receive approval for medical devices, companies must comply with certain regulations, which take a long time. Moreover, usage of minimally invasive procedures in the treatment of uterine fibroids can lead to urinary tract injury among women.
The U.S. uterine fibroids treatment market was valued at US$ 236.7 Mn in 2019 and is forecast to reach a value of US$ 298.5 Mn by 2027 at a CAGR of 3.0% between 2020 and 2027. Major factors driving the growth of U.S. uterine fibroid treatment market during the forecast period include high incidence among women, and technological advancements in medical devices.
Hysterectomy held dominant position in the U.S. uterine fibroids treatment market in 2019, accounting for 79.0% share in terms of value, followed by myomectomy and endometrial ablation, respectively. Uterine fibroids majorly develop in 50% of women, which have led to increased rate of hysterectomy i.e. removal of the uterus.
The prevalence of women with non–cavity-distorting uterine fibroids is lower in women with polycystic ovary syndrome than in those with unexplained infertility. For instance, according to a study by Yale University School of Public Health, published in The American Society for Reproductive Medicine’s journal Fertility and Sterility in March 2019, the prevalence of women with non–cavity-distorting uterine fibroids in women with polycystic ovary syndrome was 6.7% compared to 12.4% in those with unexplained infertility.
Use of UPA in the treatment of uterine fibroids may lead to reduction in the size of myomas. For instance, in January 2020, researchers from Pomeranian Medical University in Szczecin, Poland, reported that use of UPA led to reduced size of myomas and fibroids.
U.S. Uterine Fibroids Treatment Market: Competitive Landscape
Major players operating in the U.S. uterine fibroids treatment market include, Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.
U.S. Uterine Fibroids Treatment Market: Key Developments
March 2020: Olympus Corporation announced that an updated guidance from the Food and Drug Administration mandates that laparoscopic power morcellation in gynecological procedures be conducted with an approved containment device